The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis
Key facts
- Who runs it
- University of British Columbia
- Where
- Canada11 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 52 people enrolled
- Started
- 2 Aug 2019
- Ended
- 17 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methotrexate
- Ondansetron
- Folic/folinic acid
- Record updated
- 29 June 2025
Who can take part
- Age
- 4 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Ages 4-16 years
- Diagnosis of JIA as per ILAR criteria [1], irrespective of JIA category
- Followed at a CAPRI centre in Canada
- Starting methotrexate to control JIA manifestations (arthritis, uveitis, psoriasis). (Female subjects of child bearing potential who are taking methotrexate for JIA cannot be pregnant, breastfeeding, or planning a pregnancy while on the drug and females of childbearing potential who are sexually active must use highly effective medically acceptable contraception. Subjects who stop methotrexate during the study will also discontinue ondansetron.)
- Informed written consent to participate
- Participating in the CAPRI JIA Registry
Who cannot take part
- Previous use of methotrexate
- Because the serotonin syndrome may occur when ondansetron is combined with other agents that may affect the serotonergic neurotransmitter system, patients receiving any of the serotonergic and/or neuroleptic drugs listed below will be excluded:; Triptans, SSRIs, SNRIs, lithium, sibutramine, fentanyl and its analogues, dextromethorphan, tramadol, tapendalol, meperidine, methadone, pentazocine or St. John's Wort (Hypericum perforatum), MAOIs, linezolid, methylene blue
- Known hypersensitivity to ondansetron or any components of its formulations
- Known hypersensitivity to other 5-HT3 antagonists
- Known congenital Long-QT syndrome
- Patients taking other medicinal products that lead to either QT prolongation or electrolyte abnormalities
- Patients who are pregnant or breastfeeding, or are sexually active and unwilling to practice an acceptable method of birth control
- Family unable to complete questionnaires in English or French
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Far too many kids and families live in dread over the weekly nausea and vomiting caused by methotrexate - a medicine that controls joint swelling in Juvenile Arthritis patients. If methotrexate is not tolerated, expensive alternative biological medications may be started. This registry-based pragmatic randomized controlled trial will evaluate if routine premedication with the anti-emetic drug Ondansetron, reduces nausea and vomiting and increases the proportion of children able to continue methotrexate. By preventing nausea before it starts, the investigators hope to give kids and families a better quality of life and see a more cost-effective use of medication.
The 2 groups in the trial
- Ondansetron premedicationTreatment being tested
Methotrexate and folic/folinic acid as prescribed by physician. Ondansetron: 2 mg if \<15Kg, 4 mg if 15-30Kg, 8 mg if \>30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake. To be started from the very first dose of methotrexate.
Treatment: Methotrexate, Ondansetron, and Folic/folinic acid
- Ondansetron as neededExisting treatment, for comparison
Methotrexate and folic/folinic acid as prescribed by physician. ONLY children who report nausea/vomiting during regular care will be prescribed ondansetron at the same dose as in experimental group (2 mg if \<15Kg, 4 mg if 15-30Kg, 8 mg if \>30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake), as per the attending rheumatologist's discretion
Treatment: Methotrexate, Ondansetron, and Folic/folinic acid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 29 June 2025